F8 and hemophilia A: Currently, plasma-purified native FVIII or recombinant human BDD-FVIII protein is the principal treatment for hemophilia A. The recombinant human FVIII protein is produced by CHO cells using serum-free culture medium, which reduces the risks of blood-sourced pathogens [19,20].